<DOC>
	<DOCNO>NCT02615041</DOCNO>
	<brief_summary>The study randomize three-way crossover study . Each subject receive meropenem three regimen room temperature consecutively : ( ) bolus injection 1 g meropenem 10 min every 8 h 24 h , ( ii ) 3-h infusion 1 g meropenem via infusion pump constant flow rate every 8 h 24 h , ( iii ) 3-h infusion 2 g meropenem via infusion pump constant flow rate every 8 h 24 h. Clinical laboratory data Age , Sex , Body weight , Electrolyte , Vital sign , APACHE II score , BUN , Cr , Blood culture collect . Nine patient enrol study . After completion meropenem therapy 3 day study , patient receive sensitive antibiotic eradicate bacterial infection . Meropenem pharmacokinetic study carry administration third dose regimen ( 16 24 h start regimen ) . Blood sample ( approximately 5 ml ) obtain direct venipuncture follow time : ( time zero ) 10 30 min 1 , 1.5 , 2 , 2.5 , 3.5 , 4 , 4.5 , 5 , 6 , 8 h third dose regimen . The concentration meropenem determine reverse-phase high-performance liquid chromatography . Concentration meropenem plasma simulate Monte Carlo technique ( Computer model ) get PK/PD index ( 40 % T &gt; MIC ) report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response )</brief_summary>
	<brief_title>The Pharmacodynamics Meropenem Patient With Ventilator-associated Pneumonia</brief_title>
	<detailed_description>Introduction : Meropenem carbapenem antibacterial agent broad spectrum activity several pathogen . In common -lactams , main pharmacokinetic/pharmacodynamic parameter correlate therapeutic efficacy T &gt; MIC , administration continuous infusion prefer route maximize parameter . However , tropical country stability meropenem important consideration continuous infusion use . Objective : The aim study demonstrate T &gt; MIC meropenem administer 3-h infusion compare administered bolus injection . Study design : The study conduct nine patient ventilator-associated pneumonia . Each subject receive meropenem three regimen consecutively : ( ) bolus injection 1 g every 8 h 24 h ; ( ii ) 3-h infusion 1 g every 8 h 24 h ; ( iii ) 3-h infusion 2 g every 8 h 24 h. Sample collection : Meropenem pharmacokinetic study carry administration third dose regimen ( 16 24 h start regimen ) . Blood sample ( approximately 5 ml ) obtain direct venipuncture follow time : ( time zero ) 10 30 min 1 , 1.5 , 2 , 2.5 , 3.5 , 4 , 4.5 , 5 , 6 , 8 h third dose regimen . Meropenem assay : The concentration meropenem determine reverse-phase high-performance liquid chromatography . Cefepime ( 100 mcg/ml ) use internal standard , sample extract method Ozkan et al . Clinical data pathogen collection : 1 . Initial patient demographic data ( age , sex , weight , diagnosis , APACHE II score ) collect upon enrollment study . 2 . The Gram negative bacillus isolate sputum 9 patient collect MIC meropenem pathogen determine E test upon enrollment study . Duration study : Patients receive meropenem 3 day Pharmacokinetic pharmacodynamic analysis : Concentration meropenem plasma simulate Monte Carlo technique ( Computer model ) get PK/PD index ( 40 % T &gt; MIC ) report % PTA ( Probability Target Attainment ) % CFR ( Cumulative Faction Response ) Sample Size : Nine patient VAP enrol study .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<criteria>The patient eligible study meet follow criterion : 1. old 18 year 2. clinical suspicion VAP , define new persistent infiltrate chest radiography associate least one followingâ€”purulent tracheal secretion , temperature 38.3 celsius high , leukocyte count high 10000 . Patients exclude study pregnant circulatory shock ( define systolic blood pressure 90 mmHg poor tissue perfusion ) document hypersensitivity meropenem estimate creatinine clearance ( determine CockcroftGault method ) 60 ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Meropenem</keyword>
	<keyword>Ventilator-Associated Pneumonia</keyword>
	<keyword>population pharmacokinetics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>